Development of a CYP2C19 Genotype Guided Dosing Algorithm for Voriconazole

被引：0
|
作者：
Mangal, Naveen [1 ]
Hamadeh, Issam [2 ]
Samant, Tanay [1 ]
Schmidt, Stephan [1 ]
机构：
[1] Univ Florida, Coll Pharm, Ctr Pharmacometr & Syst Pharmacol, Orlando, FL USA
[2] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2014年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
T-031
引用
收藏
页码：S53 / S53
页数：1
相关论文
共 50 条
  • [21] CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole
    Adachi, K
    Katsube, T
    Kawamura, A
    Takashima, T
    Yuki, M
    Amano, K
    Ishihara, S
    Fukuda, R
    Watanabe, M
    Kinoshita, Y
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (10) : 1259 - 1266
  • [22] CYP2C19 Genotype and Cardiovascular Events
    Mega, Jessica L.
    Topol, Eric J.
    Sabatine, Marc S.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (14): : 1482 - 1483
  • [23] CYP2C19 genotype: a moving target?
    Zembles, Tracy N.
    Marcuccilli, Charles J.
    Sander, Tara L.
    Simpson, Pippa
    PHARMACOTHERAPY, 2012, 32 (10): : E236 - E236
  • [24] Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients
    Lin, Xiao-bin
    Li, Zi-wei
    Yan, Miao
    Zhang, Bi-kui
    Liang, Wu
    Wang, Feng
    Xu, Ping
    Xiang, Da-xiong
    Xie, Xu-biao
    Yu, Shao-jie
    Lan, Gong-bin
    Peng, Feng-hua
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (07) : 1587 - 1597
  • [25] Pharmacokinetics of Intravenous Voriconazole in Obese Patients: Implications of CYP2C19 Homozygous Poor Metabolizer Genotype
    Moriyama, Brad
    Jarosinski, Paul F.
    Figg, William D.
    Henning, Stacey A.
    Danner, Robert L.
    Penzak, Scott R.
    Wayne, Alan S.
    Walsh, Thomas J.
    PHARMACOTHERAPY, 2013, 33 (03): : e19 - e22
  • [26] Nocturnal acid inhibition by different dosing schemes of rabeprazole in relation to CYP2C19 genotype
    Sugimoto, M
    Furuta, T
    Shirai, N
    Kajimura, M
    Sakurai, S
    Ohashi, K
    Ishizaki, T
    GASTROENTEROLOGY, 2004, 126 (04) : A335 - A336
  • [27] CYP2C19 Genotype and Cardiovascular Events Reply
    Nissen, Steven E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (14): : 1485 - 1485
  • [28] CYP2C19 Genotype and Outcomes of Clopidogrel Treatment
    Siasos, Gerasimos
    Tousoulis, Dimitris
    Stefanadis, Christodoulos
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (05): : 481 - 482
  • [29] Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections
    Lamoureux, Fabien
    Duflot, Thomas
    Woillard, Jean-Baptiste
    Metsu, David
    Pereira, Tony
    Compagnon, Patricia
    Morisse-Pradier, Helene
    El Kholy, Mona
    Thiberville, Luc
    Stojanova, Jana
    Thuillez, Christian
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2016, 47 (02) : 124 - 131
  • [30] CYP2C19 genotype and the PPIs - focus on rabeprazole
    Lim, PWY
    Goh, KL
    Wong, BCY
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 20 : S22 - S28
12345